We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: How Many Melanoma Patients Did the FDA Kill?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > How Many Melanoma Patients Did the FDA Kill?
BusinessPublic Health

How Many Melanoma Patients Did the FDA Kill?

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

By my estimate, more than 1,000 people have died prematurely because of foot-dragging by the FDA. Here’s why. After an “expedited” analysis that lasted a year and a half, the FDA has finally approved Bristol-Myers Squibbs’ Yervoy (ipilimunab) for metastatic melanoma. The deadliest type of skin cancer, melanoma killed 8,700 Americans last year, according to the National Cancer Institute. BMS submitted its application to the FDA on August 18, 2010, with a target date for approval of December 25. On November 2, the FDA pushed out the target date. On March 25, the FDA approved the lifesaving medicine. So, the question is: How many patients did the FDA kill by delaying the medicine? Well, 46 percent of the subjects taking the drug were alive one year later, and 20 percent were alive two years later. In the control group, only 25 percent survived one year, and 14 percent two years. The difference between 46 percent and 25 percent is 21 percent. 21 percent of 8,700 is 1,827 lives. Similarly, the difference between 20 percent and 14 percent is 6 percent, or 522 of 1,827 lives. Assuming that BMS was willing to supply the medicine as of August 18, 2010, the FDA’s initial period of review (to December 25) took 129 days. This implies that 645 melanoma patients died a year earlier than they would have without the legal requirement for FDA approval. However, because the FDA delayed a further 90 days (to March 25), 450 more patients died a year early. The point estimate for the total number of melanoma patients who died a year early is 1,095. Of course, many of those would have died after another year. The delay only cost 313 patients two years of life. But I hardly think that’s a comfort to melanoma victims and their families.

TAGGED:FDApublic health
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026
Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026

You Might also Like

patient engagement
Public Health

Person-Centered HealthCare BONUS!: A New Level of Patient Engagement

March 8, 2013

FDA Approves Middle of the Night Sleeping Pill–Treatments Are Getting Specific–Is This Personalized Medicine?

November 27, 2011
Infographic: Can Physicians Practices Remain Profitable?
Business

Can Physician Practices Remain Profitable?

June 1, 2013

How Does Your Hospital Compare on Hospital Acquired Conditions?

April 20, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?